Clinical Trial

Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss. Specifically, sodium thiosulfate has been found to protect the cells in the inner ear, and may therefore prevent hearing loss. Mannitol can help sodium thiosulfate enter the inner ear, and ponteially increase the effectiveness of sodium thiosulfate. This study aims to assess the efficacy of sodium thiosulfate and mannitol to reduce the hearing impairment caused by cisplatin chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-11-18; most recent amendment 2023-04-12.
Status change: Not Yet Recruiting → Recruiting 2023-04-12
Trial Details
NCT Number NCT05129748
Lead Sponsor Sunnybrook Health Sciences Centre
Conditions Ototoxic Hearing Loss
Enrollment 92 participants
Start Date 2023-02-15
Primary Completion 2027-01 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2023-04-14